Image Source: AsiaOne
New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percentGlobeNewswireJanuary 26, 2021Trial met primary endpoint and key secondary endpoints with high statistical significanceResults from more than 1,000 high-risk patients were consistent with previous dataIn November, Lilly submitted a EUA request to the FDA for etesevimab and bamlanivimab together for mild to moderate COVID-19 in high-risk patients, which remains under review by the FDAFindings from BLAZE-4 trial provide data on lower doses of etesevimab and bamlanivimab togetherSHANGHAI, China, Jan.
Source: AsiaOne